Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$11.55 USD

11.55
7,595,263

+0.19 (1.67%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $11.56 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Services

Better trading starts here.

Zacks News

Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.87% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.

Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates

Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.

Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.

Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 15.09% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 35.56% and 4.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip

Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Viatris (VTRS) Beats Q3 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 5.41% and 1.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Viatris (VTRS) Ahead of Earnings?

Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.